Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Enzalutamide in Castration-Resistant Prostate Cancer
NCT03829930Phase 1Terminated
- Sponsor
- George Washington University
- Start
- May 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in prostate adenocarcinoma, sponsored by George Washington University. Primary endpoint: Maximum Tolerated Dose at 18 months. Started May 2019; status: terminated.
02
Drugs
entinostat
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT03829930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829930.